Cellworks

Cellworks is a leader in Precision Drug Development and Personalized Therapy Biosimulation.

[Cellworks @CellworksLife]

At the #AACR2026 Annual Meeting last week, #Cellworks presented 3 studies showing how mechanistic AI can advance precision, access & explainability in oncology. Thanks @CharuAggarwalMD & @TejasPatilMD for the collaboration.
#NSCLC #PersonalizedOncology #PrecisionDrugDevelopment

[Cellworks @CellworksLife]

Cellworks Reception during JPM Week.
Thank you to everyone who joined us at Mastro’s Steakhouse in SF for an evening of engaged conversations and new connections around precision drug development in biopharma.
#JPMWeek #Cellworks #Biopharma

[Cellworks @CellworksLife]

Wishing our community a joyful holiday season! 
We’re grateful for the clinicians, researchers, and partners who share our commitment to improving patient outcomes - together.
Happy Holidays!

#HappyHolidays #PersonalizedMedicine #PersonalizedOncology #Biosimulation #Cellworks

[Cellworks @CellworksLife]

At #SITC2025, Cellworks shared new insights into genomic markers shaping chemo-immunotherapy response in advanced #NSCLC. Findings highlight the Cellworks Platform’s ability to biosimulate tumor behavior and guide personalized treatment.
Read here - https://t.co/Yyl1Rec3Fv

[Cellworks @CellworksLife]

At #WCLC25, Cellworks shared new NSCLC findings: https://t.co/Xxnsjh9DGF. The study predicted which patients benefit from checkpoint inhibitors - 30.8 vs. 12 mo survival. We're grateful to collaborator Dr. Charu Aggarwal(UPenn) for advancing this work with us -
#Cellworks

[Cellworks @CellworksLife]

We are honored to share Cellworks’ myCare-040 study at #WCLC25 - https://t.co/jUOAIqkD1D
Our reception with Dr. Charu Aggarwal highlighted both groundbreaking science in metastatic #NSCLC and the inspiring community driving oncology forward.

[Cellworks @CellworksLife]

Cellworks Reception at #ASCO25. 
Our COO Brian Battey and Chief Development Officer James Wingrove had the opportunity to speak with John Hennessy, Principal at Valuate Health Consultancy, about advancing personalized therapy selection in cancer care.
#Cellworks

[Cellworks @CellworksLife]

Beyond AI: The Critical Role of Biology in Personalized Cancer Therapy
There is widespread hype around using AI to predict patient outcomes in cancer care.
Read the full blog to learn how Cellworks is moving beyond the AI black box: https://t.co/WdOqf3EJvI
#PersonalizedOncology

[Cellworks @CellworksLife]

We are proud to announce that the Cellworks Computational Biosimulation Lab in Franklin, Tennessee has achieved CLIA Certification of Compliance from the Centers for Medicare and Medicaid Services!
Read the press release - https://t.co/Qc2ugPOD3S
#Cellworks #PersonalizedMedicine

[Cellworks @CellworksLife]

As we welcome in 2025, we'd like to honor the courage of cancer patients & the dedication of oncologists, researchers, and drug developers advancing personalized medicine. Let's continue to drive innovations & bring hope to make a difference in patient outcomes. Happy New Year!

[Cellworks @CellworksLife]

We were thrilled that Deepak Lala, Cellworks Head of Personalized Medicine, was asked to speak at the Project Management Practitioners Conference 2024 (PMPC-2024), where he introduced Cellworks and our groundbreaking advancements in Computational Personalized Medicine #Cellworks

[Cellworks @CellworksLife]

Check out our latest blog by Cellworks Chief Scientific Officer, Dr. Ansu Kumar, exploring whether IDH mutations can predict venetoclax response in AML patients.
Read more here: https://t.co/eAnsiXaVNE
#AML #Biosimulation #PrecisionMedicine #IDHMutations #Cellworks

[Cellworks @CellworksLife]

Himanshu Grover, Lead Scientist R&D & Shweta Kapoor, Director of R&D presented new findings at #ESM02024 on how combining Biosimulation with tumor Microenvironment modeling improves predictions of immunotherapy in NSCLC patients. 
Read the press release - https://t.co/qNiCpRCQxa

[Cellworks @CellworksLife]

Results from our new study unveiled at #ESMO24, showed how we identified homologous recombination deficiency(HRD) beyond BRCA mutation status, providing more comprehensive predictions of patient response to PARPi therapies.
Read details here -
https://t.co/deEZnautY4
#Cellworks

[Cellworks @CellworksLife]

Our study presented by Dr.Klein at @IASLC 2024 World Conference on Lung Cancer showcases how the Cellworks biosimulation platform accurately predicts which NSCLC patients will benefit most from combining chemotherapy with immunotherapy.
Read announcement-
https://t.co/rFAsAPmcAl

[Cellworks @CellworksLife]

Read the Cellworks Personalized Therapy Biosimulation study presented @IASLC 2024 World Conference on Lung Cancer in San Diego that predicted chemotherapy benefit in osimertinib-treated NSCLC patients with EGFR mutations - https://t.co/IvUhWL0TL5
#WCLC24 #Cellworks

[Cellworks @CellworksLife]

Discover how a new combination of Ruxolitinib & Sorafenib offers hope for JAK2-mutant Myelofibrosis patients. Our predictive biosimulation approach uncovers synergistic effects that go beyond targeting the JAK2 mutation alone
https://t.co/TsA3aiBQLP
#PrecisionMedicine #Cellworks

[Cellworks @CellworksLife]

Read the article published by Precision Medicine Online : Cellworks Aims to Validate Clinical Decision Support Capabilities of Computational Model. We thank Avera Cancer Institute, especially Tobias Meissner, for partnering with us in the myCare-101 study.
https://t.co/L5WTezoxz1

[Cellworks @CellworksLife]

Dr. Michael Castro, CMO of Cellworks, will be a panelist at "The Repurposing Revolution" event on October 15, 2024, in London and online. Organized by Yes to Life, this forum is dedicated to exploring Repurposed Drugs for cancer treatment. Book tickets : https://t.co/BD3Xm0vEKq

[Vernon Bainton @V_Bainton]

Always great to see familiar folks at #ASCO24

Dr Michael Castro CMO @CellworksLife doing incredible work in computational biology, precision drug development and predictive personalised #oncology treatment